Dr. O'Regan Discusses the Future of Treatment in HER2+ Breast Cancer

Ruth M. O'Regan, MD
Published: Tuesday, May 16, 2017



Ruth O’Regan, MD, division head of Hematology and Oncology in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health, discusses the potential of future treatments for patients with HER2-positive breast cancer.

Checkpoint inhibitors are garnering a lot of interest in HER2-positive breast cancer, specifically in the estrogen receptor (ER)-negative population, says O’Regan.

ER-positive/HER2-positive cancers are very heterogeneous, some of which have a luminal A phenotype. O’Regan says that there might be promise in treating these patients with HER2-targeted therapy, instead of chemotherapy.
 
SELECTED
LANGUAGE


Ruth O’Regan, MD, division head of Hematology and Oncology in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health, discusses the potential of future treatments for patients with HER2-positive breast cancer.

Checkpoint inhibitors are garnering a lot of interest in HER2-positive breast cancer, specifically in the estrogen receptor (ER)-negative population, says O’Regan.

ER-positive/HER2-positive cancers are very heterogeneous, some of which have a luminal A phenotype. O’Regan says that there might be promise in treating these patients with HER2-targeted therapy, instead of chemotherapy.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Community Practice Connections™: A Better Way to Stop Pain: Paths Toward Responsible Postsurgical Pain Management for Patients With Breast CancerMay 31, 20191.5
Publication Bottom Border
Border Publication
x